SCHEMBL1101883

SCHEMBL1101883

CCN1CCN(c2ccccc2)CC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNA7 P36544 2/20 1.00
SIGMAR1 Q99720 3/20 0.71
DRD2 P14416 2/20 0.71
KDM4E B2RXH2 2/20 0.66
MAPT P10636 2/20 0.66
GFER P55789 2/20 0.66
GAA P10253 1/20 0.66
RAD52 P43351 1/20 0.66
SMN1; SMN2 Q16637 1/20 0.66
DRD4 P21917 1/20 0.62
KCNH2 Q12809 1/20 0.62
HTR1A P08908 1/20 0.58
ALDH1A1 P00352 1/20 0.58
L3MBTL1 Q9Y468 1/20 0.58
CYP2D6 P10635 1/20 0.56
MEN1 O00255 1/20 0.55
KMT2A Q03164 1/20 0.55
KDM1A O60341 1/20 0.55
ADRA2A P08913 1/20 0.55
ADRA2B P18089 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL11555541 0.98 CHRNA7 (0.96) CHRNA7SIGMAR1DRD2KDM4EMAPT
SCHEMBL15304372 0.92 CHRNA7 (0.85) CHRNA7SIGMAR1DRD2KDM4EMAPT
Isothiocyanate SCHEMBL2895505 0.89 CHRNA7 (0.79) CHRNA7SIGMAR1DRD2KDM4EMAPT
SCHEMBL12319455 0.88 CHRNA7 (0.79) CHRNA7SIGMAR1DRD2KDM4EMAPT
SCHEMBL28852004 0.88 CHRNA7 (0.78) CHRNA7SIGMAR1DRD2KDM4EMAPT
SCHEMBL12319831 0.84 CHRNA7 (0.71) CHRNA7SIGMAR1DRD2KDM4EMAPT
SCHEMBL3453669 0.83 DRD2 (1.00) CHRNA7SIGMAR1DRD2DRD4KCNH2
SCHEMBL9041083 0.82 KCNH2 (0.80) CHRNA7SIGMAR1DRD2DRD4KCNH2
SCHEMBL81930 0.81 GAA (0.69) CHRNA7KDM4EMAPTGFERGAA
SCHEMBL576454 0.81 LMNA (0.67) CHRNA7SIGMAR1DRD2MAPTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 182 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101048405-A Aryl-substituted piperazine derivatives NEUROGEN CORP (US) 2007-10-03 CN claimed
CN-1257896-C Funcitonal molecule material containing four tertiary amine branches and preparation method UNIV FUDAN (CN) 2006-05-31 CN claimed
CN-1539833-A Funcitonal molecule material containing four tertiary amine branches and preparation method 复旦大学 2004-10-27 CN claimed
EP-0548798-A1 Antiviral agent SANWA KAGAKU KENKYUSHO CO., LTD. (JP) 1993-06-30 EP claimed
US-20230365582-A1 NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY ON PROSTAGLANDIN E2 RECEPTOR AND USES THEREOF KANAPH THERAPEUTICS INC. (KR) 2023-11-16 US disclosed
US-20230346797-A1 INHIBITORS OF THE PLASMODIAL SURFACE ANION CHANNEL AS ANTIMALARIALS THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2023-11-02 US disclosed
CN-116848107-A Compounds and their use as PDE4 activators 米罗尼德有限公司 2023-10-03 CN disclosed
WO-2023158221-A1 PHARMACEUTICAL COMPOSITION FOR TREATING CANCER, COMPRISING ANTICANCER AGENT AND NOVEL COMPOUND HAVING INHIBITORY ACTIVITY WITH RESPECT TO PROSTAGLANDIN E2 RECEPTORS 주식회사 카나프테라퓨틱스 2023-08-24 WO disclosed
US-20230002383-A1 NOVEL FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE PRAEVENTIX, LLC 2023-01-05 US disclosed
US-20220389019-A1 TrkB POSITIVE ALLOSTERIC MODULATORS INSERM - INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (FR) 2022-12-08 US disclosed
US-20220393117-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORPORATION (US) 2022-12-08 US disclosed
EP-2696873-B1 PLASMODIAL SURFACE ANION CHANNEL INHIBITORS FOR THE TREATMENT OR PREVENTION OF MALARIA US HEALTH (US) 2022-08-03 EP disclosed
US-5378690-A Treatment of angiotensin induced hypertension SANKYO COMPANY, LIMITED (JP) 1995-01-03 US disclosed
EP-0548798-A1 Antiviral agent SANWA KAGAKU KENKYUSHO CO., LTD. (JP) 1993-06-30 EP disclosed
EP-0274259-A2 New renin-inhibitory oligopeptides, their preparaton and their use Sankyo Company Limited (JP) 1988-07-13 EP disclosed
US-4668681-A ANTIALLERGENS, ANAPHYLAXIS, MOTION SICKNESS SOCIETE CORTIAL, S.A. (FR) 1987-05-26 US disclosed
EP-0078756-B1 2-(4-PHENYL-PIPERAZINYLETHYL) ANILINES, PROCESS FOR THEIR PREPARATION AND THEIR USE IN MEDICINE CORTIAL S.A. (FR) 1986-03-12 EP disclosed
EP-0078757-B1 IMINES OF 2-(4-PHENYL-PIPERAZINYLETHYL) ANILINES, PROCESS FOR THEIR PREPARATION AND THEIR USE IN MEDICINE CORTIAL S.A. (FR) 1985-09-04 EP disclosed
EP-0078756-A1 2-(4-Phenyl-piperazinylethyl) anilines, process for their preparation and their use in medicine CORTIAL S.A. (FR) 1983-05-11 EP disclosed
EP-0078757-A1 Imines of 2-(4-phenyl-piperazinylethyl) anilines, process for their preparation and their use in medicine CORTIAL S.A. (FR) 1983-05-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220393117-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES NPY1R, NPY2R, KISS1R CHRNA7 1524/4885SIGMAR1 776/4885DRD2 1670/4885
US-20230346797-A1 INHIBITORS OF THE PLASMODIAL SURFACE ANION CHANNEL AS ANTIMALARIALS SLC8B1, CATSPER1, SLC9A1 CHRNA7 2723/4885SIGMAR1 1844/4885DRD2 4270/4885
US-20230365582-A1 NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY ON PROSTAGLANDIN E2 RECEPTOR AND USES THEREOF PTGER1, PTGIR, PTGDR2 CHRNA7 2115/4885SIGMAR1 420/4885DRD2 2570/4885
US-20220389019-A1 TrkB POSITIVE ALLOSTERIC MODULATORS HTT, NTRK2, BDNF CHRNA7 60/4885SIGMAR1 1243/4885DRD2 1688/4885
US-20230002383-A1 NOVEL FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE HTR7, HTR1A, HTR2C CHRNA7 40/4885SIGMAR1 38/4885DRD2 66/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.